The treatment of rheumatoid arthritis has improved dramatically in recent years with the advent of the latest generation of disease-modifying antirheumatic drugs. Despite these advances, in some patients inflammation is not diminished sufficiently to prevent irreversible musculoskeletal damage, thus requiring surgical intervention to reduce pain and improve function. In these cases, the orthopaedic surgeon frequently encounters patients on a drug regimen consisting of nonsteroidal anti-inflammatory drugs, glucocorticoids, methotrexate, and biologic agents (disease-modifying antirheumatic drugs). Consultation with a rheumatologist is recommended, but the surgeon also should be aware of these medications that could potentially affect surgical outcome. Prudent perioperative management of these drugs is required to optimize surgical outcome. A balance must be struck between minimizing potential surgical complications and maintaining disease control to facilitate postoperative rehabilitation of patients with rheumatoid arthritis.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
93% Article relates to my practice (31/33)
3% Article does not relate to my practice (1/33)
3% Undecided (1/33)
2

Will this article lead to more cost-effective healthcare?

81% Yes (27/33)
18% No (6/33)
0% Undecided (0/33)
3

Was this article biased? (commercial or personal)

6% Yes (2/33)
90% No (30/33)
3% Undecided (1/33)
4

What level of evidence do you think this article is?

6% Level 1 (2/33)
15% Level 2 (5/33)
42% Level 3 (14/33)
12% Level 4 (4/33)
24% Level 5 (8/33)